AstraZeneca Q3 revenue rises 7% on Oncology unit strength
AstraZeneca Q3 revenue rises 7% on Oncology unit strength
Overview
UK pharma group's Q3 revenue rose 7% yr/yr, beating analyst expectations
Core EPS for Q3 increased 17% and beat analyst expectations
Growth in Oncology, R&I and Rare Disease offset declines in some cardiovascular drugs
Outlook
AstraZeneca expects FY 2026 total revenue to rise by a mid-to-high single-digit percentage
Company forecasts FY 2026 core EPS to grow by a low double-digit percentage
AstraZeneca anticipates FY 2026 core tax rate between 18% and 22%
Result Drivers
ONCOLOGY, R&I, RARE DISEASE GROWTH - Co said double-digit growth in Oncology, Respiratory & Immunology, and Rare Disease segments offset declines in some cardiovascular drugs
PRODUCT MIX, PRICING PRESSURE - Gross margin benefited from positive product mix, but was partly offset by pricing headwinds and loss of exclusivity, especially in China
GENERIC COMPETITION - Loss of exclusivity and generic competition weighed on Farxiga and Brilinta sales
Company press release: ID:nRSd0827Ba
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $16.21 bln | $16.03 bln (16 Analysts) |
Q3 Core EPS | Beat | $2.79 | $2.59 (15 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for AstraZeneca PLC is GBp16,000.00, about 22.6% above its October 29 closing price of GBp13,052.00
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago
Reuters Recommended Reads
Oct 28 - GSK pipeline doubts, vaccine underperformance overshadow sales beat
Oct 28 - Biogen Q3 revenue beats on Apellis acquisition, product demand
Oct 29 - Merck Q3 profit beats on Keytruda demand
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on AstraZeneca
See all newsAstraZeneca fends off lawsuit over alleged Soliris drug monopoly (updated)
AstraZeneca fends off lawsuit over alleged Soliris drug monopoly
Sofinnova closes €725 million fund to back European biotech expansion
AstraZeneca gets US nod for expanded Imfinzi use, new rare-disease therapy
UK Stocks-Factors to watch on November 16 (updated)